Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1618-7601

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations ; day:20 ; month:9 ; year:2019 ; pages:1-12
The European journal of health economics ; (20.9.2019), 1-12

Creator: Holleman, Marscha S.
Al, Maiwenn J.
Zaim, Remziye
Groen, Harry J. M.
Uyl-de Groot, Carin A.

Contributor: SpringerLink (Online service)

DOI: 10.1007/s10198-019-01117-3

URN: urn:nbn:de:101:1-2020020119331788505513

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 11.08.2025, 9:43 PM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Holleman, Marscha S.
Al, Maiwenn J.
Zaim, Remziye
Groen, Harry J. M.
Uyl-de Groot, Carin A.
SpringerLink (Online service)

Other Objects (12)

Correlation of MRI quantitative perfusion parameters with EGFR, VEGF and EGFR gene mutations in non-small cell cancer

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Correlation of MRI quantitative perfusion parameters with EGFR, VEGF and EGFR gene mutations in non-small cell cancer

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Correlation of MRI quantitative perfusion parameters with EGFR, VEGF and EGFR gene mutations in non-small cell cancer

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Correlation of MRI quantitative perfusion parameters with EGFR, VEGF and EGFR gene mutations in non-small cell cancer

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

EGFR exon 20 insertion mutations in NSCLC

Correlation of MRI quantitative perfusion parameters with EGFR, VEGF and EGFR gene mutations in non-small cell cancer

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

EGFR exon 20 insertion mutations in NSCLC

Correlation of MRI quantitative perfusion parameters with EGFR, VEGF and EGFR gene mutations in non-small cell cancer

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

EGFR exon 20 insertion mutations in NSCLC

Related objects

Reset password